% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Mancuso:282976,
author = {Mancuso, Michelangelo and Lopriore, Piervito and Semmler,
Luisa and Kornblum, Cornelia},
collaboration = {group, 280th ENMC workshop study},
othercontributors = {Artuch, Rafael and Bellusci, Marcello and Bertini, Enrico
and Carelli, Valerio and Distelmaier, Felix and Hirano,
Michio and Horvath, Rita and Janssen, Mirian Ch and Karaa,
Amel and Klopstock, Thomas and Kornblum, Cornelia and
Lamperti, Costanza and Lopriore, Piervito and McFarland,
Robert and Ng, Yi Shiau and Mancuso, Michelangelo and
Prokisch, Holger and Rahman, Shamima and Schiff, Manuel and
Semmler, Luisa and Serenella, Servidei and Taivassalo, Tanja
and Vissing, John and van den Ameele, Jelle and Waller,
Katie},
title = {280th {ENMC} {I}nternational {W}orkshop: {T}he {ERN}
{EURO}-{NMD} mitochondrial diseases working group;
diagnostic criteria and outcome measures in primary
mitochondrial myopathies. {H}oofddorp, the {N}etherlands,
22-24 {N}ovember 2024.},
journal = {Neuromuscular disorders},
volume = {50},
issn = {0960-8966},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DZNE-2025-01428},
pages = {105340},
year = {2025},
abstract = {The 280th ENMC International Workshop, held in Hoofddorp,
The Netherlands, November 22-24, 2024, focused on primary
mitochondrial myopathies (PMM). The workshop aimed to update
diagnostic criteria, outcome measures, and explore new
digital health technologies (DHTs) in the context of
clinical trial design and conduct for PMM. Key points
discussed included: (i) PMM definition and phenotypes; PMM
are genetically determined mitochondrial disorders with
prominent skeletal muscle involvement with two major
phenotypes: mitochondrial myopathy (MiMy) either with or
without chronic progressive external ophthalmoplegia (PEO);
(ii) diagnostic criteria, with emphasis on the importance of
genetic testing and muscle biopsy for accurate diagnosis;
(iii) outcome measures: consensus on clinical scales,
functional tests, performance measures, and patient-reported
outcome measures (PROMs) for both adults and children; (iv)
digital health technologies, with exploration of wearable
and non-wearable technologies for gait analysis, physical
activity monitoring, and other assessments; (v) potential
and limitations of biomarkers for PMM diagnosis and
monitoring. The workshop concluded with a strong consensus
on the updated definition of PMM, its phenotypes, and the
recommended outcome measures for clinical studies. Further
research is needed to validate digital health technologies
and biomarkers for PMM.},
keywords = {Humans / Mitochondrial Myopathies: diagnosis /
Mitochondrial Myopathies: therapy / Mitochondrial
Myopathies: genetics / Netherlands / Outcome Assessment,
Health Care / Patient Reported Outcome Measures / Biomarkers
(Other) / Clinical trials (Other) / Diagnostic criteria
(Other) / Outcome measures (Other) / Primary mitochondrial
myopathy (Other)},
ddc = {610},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40273815},
doi = {10.1016/j.nmd.2025.105340},
url = {https://pub.dzne.de/record/282976},
}